NCT05687123 2026-03-18
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
15 trialsNCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT05988918 2026-03-06
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT06943755 2026-02-27
STELLAR-311
Exelixis
Phase 2/3 Recruiting
NCT04924075 2026-02-24
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07273409 2026-01-22
PANTODON
Uppsala University
Phase NA Recruiting
NCT07328607 2026-01-21
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
Minia University
Phase NA Recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT06663072 2026-01-09
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
University of Chicago
Phase 1 Recruiting
NCT06881992 2025-12-30
Tumor HI
Rezolute
Phase 3 Recruiting
NCT05040360 2025-12-15
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
Phase 2 Recruiting
NCT04520932 2025-05-25
RFANET
Institut Paoli-Calmettes
Phase NA Recruiting
NCT05037461 2024-12-18
PRIME
UMC Utrecht
Phase NA Recruiting
NCT05997056 2024-07-16
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience, Inc.
Phase 2 Recruiting
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting